Key facts
as of Sep 2026- Notable investors include Paulo Nigro, Squared Ventures.
- 2 institutional filers report fund marks on Neogenomica across 8 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Neogenomica
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Neogenomica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest Apr 20262 SEC-registered funds reported 8 fair-value marks on Neogenomica between Jan 2026 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Neogenomica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Investors
2About Neogenomica
Operator of a clinical genetics laboratory intended for genetic and immunological tests. The company uses genomics tools to guide prevention, diagnosis, and therapy in all areas of medicine provides various tests and medicines for patients, and prepares personalized medicines for their cure, enabling patients to get a cure for their rare diseases.
- Sector
- Healthcare
- HQ
- Recife, Brazil
- Founded
- 2013
- Employees
- 27
- Website
- neogenomica.com.br/
- Ownership
- Privately Held (backing)